About Keyan Salari, MD, PhD
Keyan Salari, MD, PhD is a urologic oncologist at the Massachusetts General Hospital and Harvard Medical School. He is a urologic surgeon specialized in the treatment of genitourinary cancers using open, laparoscopic, and robotic surgery techniques. His research focuses on applying cancer genomics and computational biology methods to advance precision cancer medicine for genitourinary malignancies.
Dr. Salari is a faculty member of the Department of Urology and a Urologic Oncologist at the Massachusetts General Hospital Cancer Center. He graduated with honors from the University of California at Berkeley with a B.A. in molecular and cellular biology, where he was awarded the Spencer W. Brown Award and was a Howard Hughes Medical Institute Biology Fellow. He earned his MD and PhD in Genetics from Stanford University School of Medicine in the NIH Medical Scientist Training Program. He trained in General Surgery and Urology at the Massachusetts General Hospital and subsequently completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center.
Dr. Salari’s clinical practice focuses on the surgical treatment of urologic cancers with a particular emphasis on prostate cancer, kidney cancer, and testicular cancer. He serves as Director of the Prostate Cancer Genetics Program, where families that may have a hereditary predisposition to prostate cancer are offered genetic testing, cancer screening, and support. His research interests focus on leveraging a variety of genomic technologies and computational biology methods to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.
Departments, Centers, & Programs:
Clinical Interests:
- Bladder cancer
- Cancer genetics
- Laparoscopic surgery, Robotic surgery, Open surgery
- Minimally invasive surgery
- Penile cancer
- Prostate cancer
- Renal Cancer
- Testicular cancer
- Ureteral Cancer
- Urethral Cancer
Treats:
- Adult
Locations
Mass General Cancer Center: Center for Genitourinary Cancers
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Mass General Urology
165 Cambridge St.
7th Floor
Boston, MA 02114
Phone: 857-238-3838
Medical Education
- MD, Stanford University
- Residency, Massachusetts General Hospital
- Fellowship, Memorial Sloan Kettering Cancer Center
American Board Certifications
- Urology, American Board of Urology
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
- He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 Mar;27(3):426-433. Epub 2021 Mar 4.
- AlDubayan SH, Conway JR, Camp SY, et al. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma. JAMA. 2020 Nov 17;324(19):1957-1969. doi: 10.1001/jama.2020.20457.
- Liu D, Shoag J, Poliak D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020 Apr 24;11(1):1987.
- Hanna N, Wszolek MF, Mojtahed A, et al. Multiparametric MRI/ultrasound fusion biopsy improves but does not replace standard template biopsy for the detection of prostate cancer. J Urol. 2019 May 30.
- Salari K, Kuppermann D, Preston MA, et al. Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years. J Urol. 2019 Apr;201(4):721-727.
- Wang Z, Hu L, Salari K, et al. Androgenic to Estrogenic Switch in Human Adult Prostate Gland as a result of Epigenetic Silencing of Steroid 5-α Reductase 2. J Pathol. 2017 Dec;243(4):457-467.
- Cuff J, Salari K, Esheba GE, et al. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS ONE 2013 Sep 9;8(9):e74562.
- Salari K, Spulak ME, Cuff J, et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci USA. 2012 Nov 13;109(46):E3196-205.
Yeah, the doctor is absolutely tremendous. I would go back to see him and recommend anybody else. Go see him as well.
Dr. Salari is thorough, caring and communicates my options clearly. I'm grateful for his dedication to his field and patients care.
the dr. was very nice and explained things in an easily understanding way. i would highly recomend him.
I enjoyed the provider being detailed and showing me the ultrasound to explain his point. I appreciated his politeness and respect.
I am absolutely happy with the experience during my visits to this provider's office and the care I receive,
Very happy to meet Dr. Salari. He was very helpful in answering my questions & educating me so I can decide how to treat my Prostate Cancer. I have a high level of confidence that I chose the right approach and most importantly - having Dr. Salari perform the surgery.
Dr. Salari is very focused. I always know I am in good hands.
Dr. Salari is an amazing surgeon! He is also a caring human being.
The entire experience was truly amazing. As physician for over 35 yrs as a Family Doc (PCP) but now as a patient i look at things differently then most patients. But one of the aspects of this visit that resonated with me was i was treated like a patient not as a DOCTOR patient. I got an extremely timely appointment and the entire office day was ... Read More
Excellent surgeon and bedside manner.